Patents by Inventor Dror Luger

Dror Luger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD 160 BINDING MOLECULES FOR TREATING DISEASES
    Publication number: 20230073132
    Abstract: The present invention relates to CD160 binding molecules and nucleic acid sequences encoding such molecules. In particular embodiments, the present invention provides CD160 binding molecules (e.g., monoclonal antibodies or antibody fragments) with particular light chain and/or heavy chain CDRs (e.g., selected from SEQ ID NOS:2-4, 10-12, 6-8, and 14-16) and methods for using such molecules to treat an inflammatory disease, cancer, a chronic infection, and a refractory infection, or to determine whether cells with the CD160 surface receptor are present in certain tissues or cells being examined.
    Type: Application
    Filed: December 30, 2020
    Publication date: March 9, 2023
    Inventors: Stephen E. Epstein, Dror Luger, Michael Lipinski
  • USE OF IL-23 AND IL-17 ANTIAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20140248279
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicants: Merck Sharp & Dohme Corp., The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20130323251
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: August 6, 2013
    Publication date: December 5, 2013
    Applicants: The Government of the United States of America as represented by the Secretary of the Dep. of H.H.S., Merck Sharp & Dohme Corp.
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20110142831
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: January 28, 2011
    Publication date: June 16, 2011
    Applicants: Schering Corporation, Department of Health and Human Services
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20100111954
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 6, 2010
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20100111950
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 6, 2010
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
    Publication number: 20080199460
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: August 30, 2006
    Publication date: August 21, 2008
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger